A pregnant client at 10 weeks' gestation reports exposure to a child with rubella. Which response is best?

A pregnant client at 10 weeks' gestation reports exposure to a child with rubella. Which response is best?

• A. You were wise to call. Your rubella titer indicates that you are immune and your baby is not at risk.
• B. Be sure to tell the primary health care provider in 2 weeks, as additional screening will be prescribed during your second trimester.
• C. There is no need to be concerned if you don't have a fever or rash within the next 2 days.
• D. Avoid all school-age children during pregnancy.

Answer: (A)

The key idea is that a pregnant person’s immunity to rubella determines fetal risk after exposure. If the rubella IgG titer is positive, that means immunity from prior infection or vaccination, so the fetus is effectively protected and there’s no increased risk from this exposure. In this scenario, saying that you are immune and your baby is not at risk is the appropriate, reassuring conclusion, and it reflects appropriate management: confirm immunity with serology and continue routine prenatal care. The other responses arenot as accurate. Waiting for second-trimester screening implies a nonimmune status or additional testing that isn’t needed when immunity is documented. Assuming there’s no concern without fever or rash ignores that infection can be asymptomatic and that immunity status, not symptoms alone, drives fetal risk. Suggesting to avoid all school-age children is not practical or targeted management; protection relies on validated immunity and appropriate prenatal guidance rather than broad avoidance.

The key idea is that a pregnant person’s immunity to rubella determines fetal risk after exposure. If the rubella IgG titer is positive, that means immunity from prior infection or vaccination, so the fetus is effectively protected and there’s no increased risk from this exposure. In this scenario, saying that you are immune and your baby is not at risk is the appropriate, reassuring conclusion, and it reflects appropriate management: confirm immunity with serology and continue routine prenatal care.

The other responses arenot as accurate. Waiting for second-trimester screening implies a nonimmune status or additional testing that isn’t needed when immunity is documented. Assuming there’s no concern without fever or rash ignores that infection can be asymptomatic and that immunity status, not symptoms alone, drives fetal risk. Suggesting to avoid all school-age children is not practical or targeted management; protection relies on validated immunity and appropriate prenatal guidance rather than broad avoidance.